nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—Glucose tolerance decreased—Octreotide—thymus cancer	0.0739	0.101	CcSEcCtD
Furosemide—Glucose tolerance impaired—Octreotide—thymus cancer	0.055	0.0756	CcSEcCtD
Furosemide—Pancreatitis acute—Octreotide—thymus cancer	0.0321	0.0441	CcSEcCtD
Furosemide—Abdominal bloating—Octreotide—thymus cancer	0.0311	0.0428	CcSEcCtD
Furosemide—Local reaction—Octreotide—thymus cancer	0.0268	0.0368	CcSEcCtD
Furosemide—Cholestasis—Octreotide—thymus cancer	0.0195	0.0268	CcSEcCtD
Furosemide—Nephrolithiasis—Octreotide—thymus cancer	0.0184	0.0253	CcSEcCtD
Furosemide—Injection site pain—Octreotide—thymus cancer	0.0182	0.0249	CcSEcCtD
Furosemide—Jaundice cholestatic—Octreotide—thymus cancer	0.0169	0.0232	CcSEcCtD
Furosemide—Drug interaction—Octreotide—thymus cancer	0.016	0.022	CcSEcCtD
Furosemide—Hearing impaired—Octreotide—thymus cancer	0.0156	0.0214	CcSEcCtD
Furosemide—Cramps of lower extremities—Octreotide—thymus cancer	0.0136	0.0187	CcSEcCtD
Furosemide—Urine output increased—Octreotide—thymus cancer	0.0134	0.0184	CcSEcCtD
Furosemide—Bladder pain—Octreotide—thymus cancer	0.0134	0.0184	CcSEcCtD
Furosemide—Thrombophlebitis—Octreotide—thymus cancer	0.0124	0.0171	CcSEcCtD
Furosemide—Diabetes mellitus—Octreotide—thymus cancer	0.0124	0.017	CcSEcCtD
Furosemide—SLCO2A1—neck—thymus cancer	0.0123	0.0453	CbGeAlD
Furosemide—Polyuria—Octreotide—thymus cancer	0.0123	0.0168	CcSEcCtD
Furosemide—Deafness—Octreotide—thymus cancer	0.012	0.0165	CcSEcCtD
Furosemide—Anaphylactoid reaction—Octreotide—thymus cancer	0.0111	0.0153	CcSEcCtD
Furosemide—PGD—neck—thymus cancer	0.011	0.0404	CbGeAlD
Furosemide—Irritability—Octreotide—thymus cancer	0.0103	0.0141	CcSEcCtD
Furosemide—Dehydration—Octreotide—thymus cancer	0.01	0.0137	CcSEcCtD
Furosemide—SLC12A1—hematopoietic system—thymus cancer	0.00995	0.0366	CbGeAlD
Furosemide—Cramp muscle—Octreotide—thymus cancer	0.00969	0.0133	CcSEcCtD
Furosemide—Muscular weakness—Octreotide—thymus cancer	0.00949	0.013	CcSEcCtD
Furosemide—Abdominal distension—Octreotide—thymus cancer	0.00936	0.0129	CcSEcCtD
Furosemide—Pancreatitis—Octreotide—thymus cancer	0.00912	0.0125	CcSEcCtD
Furosemide—SLC12A1—epithelium—thymus cancer	0.0091	0.0334	CbGeAlD
Furosemide—Pollakiuria—Octreotide—thymus cancer	0.00859	0.0118	CcSEcCtD
Furosemide—CA14—cardiac atrium—thymus cancer	0.00842	0.0309	CbGeAlD
Furosemide—SLCO2A1—epithelium—thymus cancer	0.0084	0.0309	CbGeAlD
Furosemide—Hyperglycaemia—Octreotide—thymus cancer	0.00839	0.0115	CcSEcCtD
Furosemide—Drowsiness—Octreotide—thymus cancer	0.00829	0.0114	CcSEcCtD
Furosemide—PGD—hematopoietic system—thymus cancer	0.00819	0.0301	CbGeAlD
Furosemide—Hepatobiliary disease—Octreotide—thymus cancer	0.00784	0.0108	CcSEcCtD
Furosemide—CA5B—hematopoietic system—thymus cancer	0.00776	0.0285	CbGeAlD
Furosemide—CA4—neck—thymus cancer	0.00719	0.0264	CbGeAlD
Furosemide—Visual impairment—Octreotide—thymus cancer	0.00717	0.00986	CcSEcCtD
Furosemide—SLCO2A1—cardiac atrium—thymus cancer	0.00698	0.0256	CbGeAlD
Furosemide—Tinnitus—Octreotide—thymus cancer	0.00694	0.00954	CcSEcCtD
Furosemide—CA1—hematopoietic system—thymus cancer	0.00685	0.0252	CbGeAlD
Furosemide—SLCO2A1—pituitary gland—thymus cancer	0.00682	0.025	CbGeAlD
Furosemide—Immune system disorder—Octreotide—thymus cancer	0.00672	0.00924	CcSEcCtD
Furosemide—Arrhythmia—Octreotide—thymus cancer	0.00665	0.00914	CcSEcCtD
Furosemide—Erythema—Octreotide—thymus cancer	0.00648	0.0089	CcSEcCtD
Furosemide—Malnutrition—Octreotide—thymus cancer	0.00648	0.0089	CcSEcCtD
Furosemide—Flatulence—Octreotide—thymus cancer	0.00639	0.00877	CcSEcCtD
Furosemide—Muscle spasms—Octreotide—thymus cancer	0.00623	0.00856	CcSEcCtD
Furosemide—PGD—cardiac atrium—thymus cancer	0.00622	0.0228	CbGeAlD
Furosemide—Vision blurred—Octreotide—thymus cancer	0.00611	0.00839	CcSEcCtD
Furosemide—PGD—pituitary gland—thymus cancer	0.00607	0.0223	CbGeAlD
Furosemide—Anaemia—Octreotide—thymus cancer	0.00599	0.00823	CcSEcCtD
Furosemide—CA2—neck—thymus cancer	0.00596	0.0219	CbGeAlD
Furosemide—Agitation—Octreotide—thymus cancer	0.00595	0.00818	CcSEcCtD
Furosemide—CA5B—cardiac atrium—thymus cancer	0.00589	0.0216	CbGeAlD
Furosemide—SLCO2A1—thyroid gland—thymus cancer	0.00588	0.0216	CbGeAlD
Furosemide—Vertigo—Octreotide—thymus cancer	0.00582	0.008	CcSEcCtD
Furosemide—SLC22A8—hematopoietic system—thymus cancer	0.00578	0.0212	CbGeAlD
Furosemide—PGD—lymphoid tissue—thymus cancer	0.00577	0.0212	CbGeAlD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00548	0.00753	CcSEcCtD
Furosemide—Dry mouth—Octreotide—thymus cancer	0.0054	0.00741	CcSEcCtD
Furosemide—SLCO2A1—lung—thymus cancer	0.00534	0.0196	CbGeAlD
Furosemide—Anaphylactic shock—Octreotide—thymus cancer	0.00529	0.00727	CcSEcCtD
Furosemide—PGD—bone marrow—thymus cancer	0.00525	0.0193	CbGeAlD
Furosemide—PGD—thyroid gland—thymus cancer	0.00524	0.0192	CbGeAlD
Furosemide—Shock—Octreotide—thymus cancer	0.0052	0.00715	CcSEcCtD
Furosemide—Nervous system disorder—Octreotide—thymus cancer	0.00519	0.00713	CcSEcCtD
Furosemide—Thrombocytopenia—Octreotide—thymus cancer	0.00518	0.00711	CcSEcCtD
Furosemide—Skin disorder—Octreotide—thymus cancer	0.00514	0.00706	CcSEcCtD
Furosemide—Hyperhidrosis—Octreotide—thymus cancer	0.00511	0.00702	CcSEcCtD
Furosemide—Anorexia—Octreotide—thymus cancer	0.00504	0.00693	CcSEcCtD
Furosemide—CA12—lung—thymus cancer	0.00502	0.0185	CbGeAlD
Furosemide—CA5B—thyroid gland—thymus cancer	0.00496	0.0182	CbGeAlD
Furosemide—CA1—lymphoid tissue—thymus cancer	0.00482	0.0177	CbGeAlD
Furosemide—PGD—lung—thymus cancer	0.00476	0.0175	CbGeAlD
Furosemide—Paraesthesia—Octreotide—thymus cancer	0.00475	0.00653	CcSEcCtD
Furosemide—Somnolence—Octreotide—thymus cancer	0.0047	0.00646	CcSEcCtD
Furosemide—Decreased appetite—Octreotide—thymus cancer	0.0046	0.00632	CcSEcCtD
Furosemide—Gastrointestinal disorder—Octreotide—thymus cancer	0.00457	0.00627	CcSEcCtD
Furosemide—Fatigue—Octreotide—thymus cancer	0.00456	0.00627	CcSEcCtD
Furosemide—Pain—Octreotide—thymus cancer	0.00452	0.00621	CcSEcCtD
Furosemide—Constipation—Octreotide—thymus cancer	0.00452	0.00621	CcSEcCtD
Furosemide—CA5B—lung—thymus cancer	0.00451	0.0166	CbGeAlD
Furosemide—CA2—hematopoietic system—thymus cancer	0.00444	0.0163	CbGeAlD
Furosemide—CA1—bone marrow—thymus cancer	0.00439	0.0161	CbGeAlD
Furosemide—Feeling abnormal—Octreotide—thymus cancer	0.00436	0.00599	CcSEcCtD
Furosemide—Gastrointestinal pain—Octreotide—thymus cancer	0.00432	0.00594	CcSEcCtD
Furosemide—Urticaria—Octreotide—thymus cancer	0.0042	0.00577	CcSEcCtD
Furosemide—Body temperature increased—Octreotide—thymus cancer	0.00418	0.00574	CcSEcCtD
Furosemide—Abdominal pain—Octreotide—thymus cancer	0.00418	0.00574	CcSEcCtD
Furosemide—CA4—cardiac atrium—thymus cancer	0.00407	0.0149	CbGeAlD
Furosemide—CA2—epithelium—thymus cancer	0.00406	0.0149	CbGeAlD
Furosemide—CA1—lung—thymus cancer	0.00398	0.0146	CbGeAlD
Furosemide—CA4—pituitary gland—thymus cancer	0.00397	0.0146	CbGeAlD
Furosemide—Hypersensitivity—Octreotide—thymus cancer	0.0039	0.00535	CcSEcCtD
Furosemide—Asthenia—Octreotide—thymus cancer	0.00379	0.00521	CcSEcCtD
Furosemide—Pruritus—Octreotide—thymus cancer	0.00374	0.00514	CcSEcCtD
Furosemide—SLCO2A1—lymph node—thymus cancer	0.00365	0.0134	CbGeAlD
Furosemide—Diarrhoea—Octreotide—thymus cancer	0.00362	0.00497	CcSEcCtD
Furosemide—Dizziness—Octreotide—thymus cancer	0.0035	0.00481	CcSEcCtD
Furosemide—CA4—bone marrow—thymus cancer	0.00343	0.0126	CbGeAlD
Furosemide—CA4—thyroid gland—thymus cancer	0.00342	0.0126	CbGeAlD
Furosemide—CA2—cardiac atrium—thymus cancer	0.00337	0.0124	CbGeAlD
Furosemide—Vomiting—Octreotide—thymus cancer	0.00336	0.00462	CcSEcCtD
Furosemide—Rash—Octreotide—thymus cancer	0.00333	0.00458	CcSEcCtD
Furosemide—Dermatitis—Octreotide—thymus cancer	0.00333	0.00458	CcSEcCtD
Furosemide—SLC22A5—cardiac atrium—thymus cancer	0.00332	0.0122	CbGeAlD
Furosemide—Headache—Octreotide—thymus cancer	0.00331	0.00455	CcSEcCtD
Furosemide—CA2—pituitary gland—thymus cancer	0.00329	0.0121	CbGeAlD
Furosemide—PGD—lymph node—thymus cancer	0.00325	0.012	CbGeAlD
Furosemide—SLC22A5—pituitary gland—thymus cancer	0.00324	0.0119	CbGeAlD
Furosemide—Nausea—Octreotide—thymus cancer	0.00314	0.00432	CcSEcCtD
Furosemide—CA2—lymphoid tissue—thymus cancer	0.00313	0.0115	CbGeAlD
Furosemide—CA4—lung—thymus cancer	0.00311	0.0114	CbGeAlD
Furosemide—CA5B—lymph node—thymus cancer	0.00308	0.0113	CbGeAlD
Furosemide—CA2—bone marrow—thymus cancer	0.00285	0.0105	CbGeAlD
Furosemide—CA2—thyroid gland—thymus cancer	0.00284	0.0104	CbGeAlD
Furosemide—SLC22A5—thyroid gland—thymus cancer	0.00279	0.0103	CbGeAlD
Furosemide—CA1—lymph node—thymus cancer	0.00272	0.01	CbGeAlD
Furosemide—CA2—lung—thymus cancer	0.00258	0.00947	CbGeAlD
Furosemide—SLC22A5—lung—thymus cancer	0.00254	0.00932	CbGeAlD
Furosemide—ALB—lymph node—thymus cancer	0.00239	0.00878	CbGeAlD
Furosemide—ABCC2—lymph node—thymus cancer	0.00224	0.00823	CbGeAlD
Furosemide—CA4—lymph node—thymus cancer	0.00213	0.00781	CbGeAlD
Furosemide—CA2—lymph node—thymus cancer	0.00176	0.00648	CbGeAlD
Furosemide—SLC22A5—lymph node—thymus cancer	0.00174	0.00637	CbGeAlD
